BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33767709)

  • 1. Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.
    Jian Y; Yang K; Sun X; Zhao J; Huang K; Aldanakh A; Xu Z; Wu H; Xu Q; Zhang L; Xu C; Yang D; Wang S
    Front Immunol; 2021; 12():639636. PubMed ID: 33767709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
    Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumor microenvironment in renal cell cancer.
    Mier JW
    Curr Opin Oncol; 2019 May; 31(3):194-199. PubMed ID: 30985497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
    Bi K; He MX; Bakouny Z; Kanodia A; Napolitano S; Wu J; Grimaldi G; Braun DA; Cuoco MS; Mayorga A; DelloStritto L; Bouchard G; Steinharter J; Tewari AK; Vokes NI; Shannon E; Sun M; Park J; Chang SL; McGregor BA; Haq R; Denize T; Signoretti S; Guerriero JL; Vigneau S; Rozenblatt-Rosen O; Rotem A; Regev A; Choueiri TK; Van Allen EM
    Cancer Cell; 2021 May; 39(5):649-661.e5. PubMed ID: 33711272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Immunotherapies for Renal Cell Carcinoma.
    Al-Marrawi MY; Holder SL
    Curr Mol Pharmacol; 2016; 9(3):252-263. PubMed ID: 26177641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
    Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
    Front Immunol; 2021; 12():657951. PubMed ID: 34531849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in kidney cancer: the past, present, and future.
    Hammers H
    Curr Opin Urol; 2016 Nov; 26(6):543-7. PubMed ID: 27533501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New immunotherapy in the treatment of advanced renal cancer.
    Muto A; Gridelli C
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):233-237. PubMed ID: 31751164
    [No Abstract]   [Full Text] [Related]  

  • 9. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies.
    Bukur J; Seliger B
    Semin Cancer Biol; 2003 Oct; 13(5):353-9. PubMed ID: 14708715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
    Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
    Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for renal cell cancer.
    Yang JC; Childs R
    J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.
    Hah YS; Koo KC
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The present state and the future perspective of immunotherapy of renal cell carcinoma].
    Kawashima H
    Nihon Rinsho; 2015 Jan; 73(1):167-74. PubMed ID: 25626324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
    Deleuze A; Saout J; Dugay F; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Crouzet L; Laguerre B; Belaud-Rotureau MA; Rioux-Leclercq N; Kammerer-Jacquet SF
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.
    Tykodi SS
    Immunotherapy; 2013 Jun; 5(6):607-19. PubMed ID: 23725284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
    Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T
    Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
    Thomas JS; Kabbinavar F
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.
    Murphy KA; James BR; Guan Y; Torry DS; Wilber A; Griffith TS
    Hum Vaccin Immunother; 2015; 11(7):1612-20. PubMed ID: 25996049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.